Return to Search
EN
Blood group incompatibility (Rh incompatibility) is a potential condition caused by differences in blood types between the mother and baby during pregnancy. Early diagnosis and appropriate treatment can prevent serious complications.
Prevention (Prophylaxis):
The risk of Rh incompatibility is determined by blood tests performed in early pregnancy. Rh-negative mothers receive Rh immune-globulin (e.g., RhoGAM) injections to prevent the formation of antibodies against the baby's blood type. These injections are typically administered between the 28th and 34th weeks of pregnancy. The first dose is usually given around the 28th week of gestation. If the baby is Rh-positive, a second dose is administered within 72 hours after birth. Rh immune-globulin prevents the mother's body from producing Rh antibodies, thereby preventing reactions that could lead to serious health problems in the newborn or affect future pregnancies.
Treatment for Affected Infants:
Treatment for infants affected by Rh incompatibility varies depending on the severity of the condition.
* Mild cases: Infants with mild Rh incompatibility can be treated with phototherapy (bilirubin lights or biliblankets) to reduce bilirubin levels. This method helps the baby's body excrete the bilirubin that causes jaundice.
* Severe cases: Blood exchange transfusions may be necessary for severely affected infants. In rare instances, if the incompatibility is severe and the baby is at risk, special blood transfusions, known as intrauterine fetal transfusions (before birth) or exchange transfusions (after birth), may be performed. Exchange transfusions replace the baby's blood with Rh-negative red blood cells, stabilizing the red blood cell level and minimizing damage caused by existing Rh antibodies in the baby's bloodstream. This procedure also aims to reduce high bilirubin levels in the blood.
Important Consequences:
If incompatibility is not detected and treated in time, severe jaundice can develop in the newborn, potentially leading to brain damage. However, jaundice is a common condition in newborns and is generally treatable.
How is Blood Incompatibility Treated?
Prevention (Prophylaxis):
The risk of Rh incompatibility is determined by blood tests performed in early pregnancy. Rh-negative mothers receive Rh immune-globulin (e.g., RhoGAM) injections to prevent the formation of antibodies against the baby's blood type. These injections are typically administered between the 28th and 34th weeks of pregnancy. The first dose is usually given around the 28th week of gestation. If the baby is Rh-positive, a second dose is administered within 72 hours after birth. Rh immune-globulin prevents the mother's body from producing Rh antibodies, thereby preventing reactions that could lead to serious health problems in the newborn or affect future pregnancies.
Treatment for Affected Infants:
Treatment for infants affected by Rh incompatibility varies depending on the severity of the condition.
* Mild cases: Infants with mild Rh incompatibility can be treated with phototherapy (bilirubin lights or biliblankets) to reduce bilirubin levels. This method helps the baby's body excrete the bilirubin that causes jaundice.
* Severe cases: Blood exchange transfusions may be necessary for severely affected infants. In rare instances, if the incompatibility is severe and the baby is at risk, special blood transfusions, known as intrauterine fetal transfusions (before birth) or exchange transfusions (after birth), may be performed. Exchange transfusions replace the baby's blood with Rh-negative red blood cells, stabilizing the red blood cell level and minimizing damage caused by existing Rh antibodies in the baby's bloodstream. This procedure also aims to reduce high bilirubin levels in the blood.
Important Consequences:
If incompatibility is not detected and treated in time, severe jaundice can develop in the newborn, potentially leading to brain damage. However, jaundice is a common condition in newborns and is generally treatable.